108 related articles for article (PubMed ID: 28215644)
1. From molecular insight to therapeutic strategy: The holistic approach for treating triple negative breast cancer.
Bhattacharya R; Banerjee K; Mukherjee N; Sen M; Mukhopadhyay A
Pathol Res Pract; 2017 Mar; 213(3):177-182. PubMed ID: 28215644
[TBL] [Abstract][Full Text] [Related]
2. Molecular stratification within triple-negative breast cancer subtypes.
Wang DY; Jiang Z; Ben-David Y; Woodgett JR; Zacksenhaus E
Sci Rep; 2019 Dec; 9(1):19107. PubMed ID: 31836816
[TBL] [Abstract][Full Text] [Related]
3. Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification.
Echavarria I; López-Tarruella S; Picornell A; García-Saenz JÁ; Jerez Y; Hoadley K; Gómez HL; Moreno F; Monte-Millan MD; Márquez-Rodas I; Alvarez E; Ramos-Medina R; Gayarre J; Massarrah T; Ocaña I; Cebollero M; Fuentes H; Barnadas A; Ballesteros AI; Bohn U; Perou CM; Martin M
Clin Cancer Res; 2018 Apr; 24(8):1845-1852. PubMed ID: 29378733
[No Abstract] [Full Text] [Related]
4. A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women.
Tseng LM; Chiu JH; Liu CY; Tsai YF; Wang YL; Yang CW; Shyr YM
Breast Cancer Res Treat; 2017 Jun; 163(2):241-254. PubMed ID: 28299476
[TBL] [Abstract][Full Text] [Related]
5. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
Bareche Y; Venet D; Ignatiadis M; Aftimos P; Piccart M; Rothe F; Sotiriou C
Ann Oncol; 2018 Apr; 29(4):895-902. PubMed ID: 29365031
[TBL] [Abstract][Full Text] [Related]
6. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
Lehmann BD; Jovanović B; Chen X; Estrada MV; Johnson KN; Shyr Y; Moses HL; Sanders ME; Pietenpol JA
PLoS One; 2016; 11(6):e0157368. PubMed ID: 27310713
[TBL] [Abstract][Full Text] [Related]
7. Identification of a minimum number of genes to predict triple-negative breast cancer subgroups from gene expression profiles.
Akhouayri L; Ostano P; Mello-Grand M; Gregnanin I; Crivelli F; Laurora S; Liscia D; Leone F; Santoro A; Mulè A; Guarino D; Maggiore C; Carlino A; Magno S; Scatolini M; Di Leone A; Masetti R; Chiorino G
Hum Genomics; 2022 Dec; 16(1):70. PubMed ID: 36536459
[TBL] [Abstract][Full Text] [Related]
8. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
Lehmann BD; Bauer JA; Chen X; Sanders ME; Chakravarthy AB; Shyr Y; Pietenpol JA
J Clin Invest; 2011 Jul; 121(7):2750-67. PubMed ID: 21633166
[TBL] [Abstract][Full Text] [Related]
9. Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer.
Chalakur-Ramireddy NKR; Pakala SB
Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29298879
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic-based combinatorial resveratrol and pterostilbene alters DNA damage response by affecting SIRT1 and DNMT enzyme expression, including SIRT1-dependent γ-H2AX and telomerase regulation in triple-negative breast cancer.
Kala R; Shah HN; Martin SL; Tollefsbol TO
BMC Cancer; 2015 Oct; 15():672. PubMed ID: 26459286
[TBL] [Abstract][Full Text] [Related]
11. Targeting triple-negative breast cancer: A clinical perspective.
Popovic LS; Matovina-Brko G; Popovic M; Punie K; Cvetanovic A; Lambertini M
Oncol Res; 2023; 31(3):221-238. PubMed ID: 37305385
[TBL] [Abstract][Full Text] [Related]
12. Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients.
Ring BZ; Hout DR; Morris SW; Lawrence K; Schweitzer BL; Bailey DB; Lehmann BD; Pietenpol JA; Seitz RS
BMC Cancer; 2016 Feb; 16():143. PubMed ID: 26908167
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
14. Role of the androgen receptor in triple-negative breast cancer.
Rampurwala M; Wisinski KB; O'Regan R
Clin Adv Hematol Oncol; 2016 Mar; 14(3):186-93. PubMed ID: 27058032
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells.
Tanei T; Choi DS; Rodriguez AA; Liang DH; Dobrolecki L; Ghosh M; Landis MD; Chang JC
Breast Cancer Res; 2016 Jan; 18(1):6. PubMed ID: 26757880
[TBL] [Abstract][Full Text] [Related]
16. Molecular subtypes of triple-negative breast cancer: understanding of subtype categories and clinical implication.
Lee YM; Oh MH; Go JH; Han K; Choi SY
Genes Genomics; 2020 Dec; 42(12):1381-1387. PubMed ID: 33145728
[TBL] [Abstract][Full Text] [Related]
17. Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes.
Lehmann BD; Colaprico A; Silva TC; Chen J; An H; Ban Y; Huang H; Wang L; James JL; Balko JM; Gonzalez-Ericsson PI; Sanders ME; Zhang B; Pietenpol JA; Chen XS
Nat Commun; 2021 Nov; 12(1):6276. PubMed ID: 34725325
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and clinicopathologic correlates of O⁶-methylguanine-DNA methyltransferase methylation status in patients with triple-negative breast cancer treated preoperatively by alkylating drugs.
Fumagalli C; Della Pasqua S; Bagnardi V; Cardillo A; Sporchia A; Colleoni M; Viale G; Barberis M; Pruneri G
Clin Breast Cancer; 2014 Aug; 14(4):285-90. PubMed ID: 24709436
[TBL] [Abstract][Full Text] [Related]
19. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
20. P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
Shapira I; Lee A; Vora R; Budman DR
Crit Rev Oncol Hematol; 2013 Nov; 88(2):284-92. PubMed ID: 23755891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
